This paper demonstrates that in the presence of indomethacin, a cyclooxygenase inhibitor, 100% of the mice died when infected with live Listeria, whereas none ofthe animals died in the absence of the drug. The death of the animals correlated with the numbers
Introduction
The ability ofperitoneal macrophages to synthesize thromboxane (Tx)' A2 remains unaltered during a local Listeria monocytogenes (LM) infection (1) whereas, in contrast, their ability to produce prostaglandin (PG) E2 and PG12 as well as leukotriene (LT) C4 are dramatically decreased (1) (2) (3) . The mechanism by which macrophage Tx synthesis is selectively conserved during in vivo activation with LM appears to be the result of the migration of blood monocytes to the site ofinfection, carrying a distinct profile ofarachidonate metabolic enzyme activities compared with resident cells (4) . Whereas resident murine peritoneal macrophages produce large amounts of PGI2, PGE2, and LTC4 compared Reprints may be obtained from Dr. Needleman, Department of Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 631 10. Received for publication 1I July 1986 and in revisedform 12 September 1986.
1. Abbreviations used in this paper: AA, arachidonic acid; LM, Listeria monocytogenes; LT, leukotriene; PEC, peritoneal exudate cells; Tx, thromboxane.
with TxA2 (1-3) when they are stimulated with an agonist, both murine and human blood monocytes produce predominantly TxA2 compared with PGE2, PG12, and LTC4 (4, 5) . Thus, the rapid migration of blood monocytes to the peritoneal cavity during infection not only increases the number of phagocytic cells capable oftaking up the bacteria but also ensures the rapid, decreased synthesis of the potent inhibitory immunomodulators, PGI2 and PGE2 (6, (7) (8) (9) while maintaining TxA2 synthesis.
However the physiological role for the conservation of macrophage TxA2 synthesis is not known because this arachidonate metabolite does not appear to regulate any cellular immune function directly (6, 10) .
All of these arachidonate products have potent effects on the vasculature during the immune response (reviewed in references 11 and 12). PGE2 and PGI2 are primary inducers of increased blood flow (13, 14) and can synergize with C5a to increase vascular permeability (15, 16) . LTC4 can also cause a direct increase in vascular permeability. Furthermore resident peritoneal cells increase the synthesis of these products in response to phagocytic stimuli in vivo (17) . An increased blood flow and vascular permeability would be advantageous at the onset of an infection by promoting an influx of immune cells, including lymphocytes, polymorphonuclear leukocytes, and monocytes to the site of an infection.
In contrast, TxA2, a potent vasoconstrictor, would be expected to decrease blood flow. Because the monocytes migrating to the site of infection can produce large amounts of TxA2 in response to various immunological stimuli including immune complexes and bacteria (4, 5), a decrease in blood flow to the site of infection may be expected with time after infection. This may be advantageous ifa decreased blood flow helped to confine the bacteria locally and thus allow the cellular effector systems of the immune response to eliminate it more effectively.
In this paper we present data that support the hypothesis that a TxA2-mediated vasoconstriction may decrease the numbers ofbacteria leaving the initial site ofinfection. Furthermore, we propose that this may be an important mechanism by which TxA2 may regulate the immune response in vivo and hence increase the survival rate of the animal.
Methods
Infection and quantitation ofbacterial loads. Adult Bl O.A/Sg Sn J (Jackson Laboratories, Bar Harbor, ME) were infected with 104-106 live LM intraperitoneally in 0.25 ml. The numbers of bacteria in the spleen were quantitated, after infection, by mincing the spleens in phosphate-buffered saline (PBS) containing 0.05% Triton X-100. The spleens were then aseptically passed through a sieve in 0.05% Triton X-100/PBS and then homogenized in a dounce homogenizer. The homogenates were serially diluted and plated on brain-heart infusion agar. Homogeneous bacterial colonies could be seen in 24 h at 370C and were counted.
Drug administration. All drugs were given intraperitoneally in pyrogen-free PBS as follows: indomethacin (Merck, Sharp and Dohme Div., West Point, PA) was initially dissolved in 0.1 M Tris buffer at pH 8.1, diluted (50-fold) into PBS, and given at 2 mg/kg in 0.25 ml; OKY1581 (Ono Pharmaceuticals, Osaka, Japan) was given at 20 mg/kg in 0.1 ml ofPBS; the stable TxA2 analog (Ono Industries Inc.) was initially dissolved in ethanol, diluted (105-fold) and given at 1 ,tg/kg in 0.1 ml; phenylephrine was given at 30 Mg/kg in 0.1 ml of PBS. PBS was administered to control animals.
Macrophage isolation and Ia expression. Macrophages were obtained from the peritpneal cavity of adult B1O.A/SgSnJ mice (Jackson Laboratories) by ravaging with PBS. 1-2 X 101 peritoneal cells estimated by hemocytometer counts were allowed to adhere to 7-mm-diameter tissue culture dishes for 2 h (370C, 5% GO2) in a-minimal essential medium (Gibco, Grand Island, NY), 5% fetal calf serum, and 100 gg penicillin/ streptomycin. The nonadherent cells were removed by washing with PBS. Surface Ia expression was determined using a radioimmunoassay. Hybridoma cells (10.2-16) secreting anti-Ia antibody (18) were grown in liter quantities and the antibody was isolated from the media by protein A-Sepharose 4B column chromatography (Pharmacia Fine Chemicals, Piscataway, NJ) (19) . The antibody was eluted from the column at pH 3.0 and then dialyzed against PBS at pH 7. To determine Ia expression, the cultured macrophages were washed with PBS and allowed to cool to 0C for 15 min. For maximum binding, 3 g/ml 1251I anti-Ia antibody was added to the macrophages in 50 ul of Hanks' balanced salt solution containing 10% bovine serum albumin and 10% normal mouse serum (pH 7.2). The cells were incubated at 0OG for 2 h (maximum binding occurred by 90 min). At the end of this incubation the unbound antibody was removed and the cells were washed quickly three times with PBS at 0C. The cells were removed from the plate by solubilization with 0.62 N NaOH. The cell-associated radioactivity was determined using a gamma counter and the cellular protein determined using the fluorescamine assay. The nonspecific binding determined using negative haplotype macrophages, B0.D2, was negligible.
Bioassay. The conversion of arachidonic acid (AA) by peritoneal exudate cells (PEC) into PGE2 and TxA2 was determined by the contraction of bioassay tissues, rat stomach, and rabbit thoracic aorta, respectively. Oxygenated (95% 02, 5% GO2) Krebs-Henseleit solution at 370C was directed over the bioassay tissues. For PGE2 production, freshly isolated PEC (I0O) were incubated with 10 MM AA in 0.1 ml PBS for 5 min at 370C and the cell suspension was pipetted directly over the bioassay tissues. For TxA2 production, freshly isolated PEC (106) were centrifuged for 2 min at 150 g, resuspended in 0.1 ml PBS, incubated with 10 AM AA for 1 min, and directed over the bioassay tissues. When indomethacin and OKY 1581 were used in vitro, the cells were incubated for 5 min at 370C before the addition of AA.
Results
Our results will show that the administration of the cyclooxygenase inhibitor, indomethacin, profoundly affected the resistence of mice to LM. First, mice infected intraperitoneally with varying doses of live LM showed an increase in the numbers of cells in the peritoneal cavity, increased numbers of activated macrophages (exemplified by Ia expression), and an increase in the numbers of bacteria found in the spleen (Table I) 104 and 105) and the increased numbers ofPEC or the activation ofperitoneal macrophages exemplified as increased Ta expression, although increasing the numbers of bacteria injected intraperitoneally resulted in more bacteria in the spleen. Increasing the bacterial dose to 3 X 105 resulted in the death of all of the mice <1 wk. With the increase in bacterial growth we also found a reduction in macrophage Ta expression, the mechanism ofwhich has not been studied. The arachidonate metabolic enzyme inhibitors, indomethacin and OKY1581, can be used to analyze the regulation of the immune response to LM by arachidonate metabolites in vivo. Indomethacin inhibits cyclooxygenase, decreasing the synthesis of PGE2, PGI2 and TxA2, whereas OKY1581 inhibits thromboxane synthase selectively. To verify the duration of inhibition of these drugs given in vivo on PEC, the rat stomach, which contrasts to PGE2, and rabbit thoracic aorta, which contracts to PGH2 and TxA2, were used as bioassay tissues (Fig. 1) . Freshly isolated mouse PEC produced PGE2 (Fig. 1 A) and TxA2 ( Fig. 1 B) in response to exogenous AA. Note that neither AA nor PEC alone had any effect on the bioassay tissues. Furthermore, the production of PGE2 was blocked by indomethacin pretreatment in vitro while TxA2 synthesis was inhibited by both indomethacin and OKY1581 treatment in vitro. When indomethacin was administered to mice intraperitoneally at 2 mg/ kg, the drug inhibited the production of PGE2 from isolated PEC for 24 h. Thus the cyclooxygenase activity of these cells was inhibited for 1 PGE2, LTC4, and TxA2 in vitro (6) . Infection with LM in the presence of indomethacin resulted in a significant increase in both the numbers of bacterial spleen counts and the death rate, which indicated an increased susceptibility to the bacteria (Table  II) . Infection with LM in the presence of iridomethacin neither changed macrophage Ia expression, nor had a significant effect on either PEC numbers (Table II) the peritoneal cavity as effectively in the presence of the drug.
Therefore the appearance of bacteria were monitored with time after the initial intraperitoneal infection. Mice infected with 105 live LM had bacteria in the spleen within 1 h (Table III A) and their levels remained constant up to 8 h. Furthermore, the dose of bacteria in the spleen within 3 h was proportional to the infective dose (Table III B) . Intraperitoneal treatment with indomethacin or the Tx synthase inhibitor, OKY1581, resulted in an increase in bacterial spleen counts by 3 h (Tables III and IV) . This increase in spleen bacterial numbers in response to indomethacin was not found if either oftwo drugs were injected simultaneously, a stable TxA2 analog or another vasoconstrictor, phenylephrine (Table IV) . However administering the stable TxA2 analog alone over a dose range of 104 to 106 LM only decreased the spleen bacteria counts by 50% at high concentrations of bacteria (data not shown), indicating that vasoconstriction may be an important secondary defense mechanism enabling the primary cellular effector systems to remove the pathogen more effectively.
Discussion
We found that when indomethacin is administered simultaneously with LM intraperitoneally, there is an increased sensi- Acknowledgments tivity to the infection. This was surprising because indomethacin has been shown to potentiate both T cell proliferation and macrophage activation in vitro (7, 8, 21, 22) . Furthermore, indomethacin potentiates the protective effects ofmuramyl dipeptide, causing an increased survival to a subsequent bacterial infection in vivo (23) . The published data indicate the inhibitory roles of PGI2 and PGE2 on immune functions in vitro and in vivo (8-10) and do not favor the notion that TxA2 is a direct stimulator of immune cells. Thus, if PGE2 and PGI2 are the only cyclooxygenase metabolites regulating the immune response in vivo, an increased resistance to bacterial infections would be expected in the presence of cyclooxygenase inhibitors. However, arachidonate metabolites also have dramatic effects on the vasculature and these effects may explain our results. These products may contribute to the regulation ofthe immune response in vivo by modulating blood flow and vascular permeability at the site of infection (1 1-16 ). For example, resident macrophages synthesize large amounts of PGI2, PGE2, and LTC4, which increase blood flow via vasodilation and promote edema via increased vascular permeability. These initial effects on the vasculature certainly facilitate the rapid migration of the effector cells of the immune response to the site of infection (reviewed in references 11 and 12). However, within hours after intraperitoneal injection ofLM, monocytes increase in numbers compromising 50% ofthe cells in the peritoneal cavity and their predominant arachidonate product is TxA2, a potent vasoconstrictor (4). Decreasing the blood flow to the site of infection should isolate the infected tissue to some degree, thus aiding the cellular immune system in its removal ofthe invading pathogen. If the infection were not confined, it may be more difficult for the immune system to efficiently eliminate the organism.
The possibility that inhibiting macrophage TxA2 synthesis with indomethacin favors the dissemination ofbacteria, resulting in the increased death rate of the infected mice, is supported by several lines of evidence. First, the effects of indomethacin are not due to the inhibition of macrophage activation in vivo be-
